Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 297

1.

Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.

Lee KM, Jeen YT, Cho JY, Lee CK, Koo JS, Park DI, Im JP, Park SJ, Kim YS, Kim TO, Lee SH, Jang BI, Kim JW, Park YS, Kim ES, Choi CH, Kim HJ; IBD study Group of Korean Association for the Study of Intestinal Diseases.

J Gastroenterol Hepatol. 2013 Dec;28(12):1829-33. doi: 10.1111/jgh.12324.

PMID:
23829336
2.

Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China.

Zhou YL, Xie S, Wang P, Zhang T, Lin MY, Tan JS, Zhi FC, Jiang B, Chen Y.

J Dig Dis. 2014 Sep;15(9):483-90. doi: 10.1111/1751-2980.12161.

PMID:
24828856
3.

Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis.

Park SH, Yang SK, Hong SM, Park SK, Kim JW, Lee HJ, Yang DH, Jung KW, Kim KJ, Ye BD, Byeon JS, Myung SJ, Kim JH.

Dig Dis Sci. 2013 Dec;58(12):3592-9. doi: 10.1007/s10620-013-2828-1. Epub 2013 Aug 25.

PMID:
23979435
4.

Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission.

Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Sociale O, Papa A, De Vitis I, Rapaccini GL, Guidi L.

Inflamm Bowel Dis. 2013 Apr;19(5):1065-72. doi: 10.1097/MIB.0b013e3182802909.

PMID:
23448790
5.

A review of infliximab use in ulcerative colitis.

Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB.

Clin Ther. 2008 Feb;30(2):223-30. doi: 10.1016/j.clinthera.2008.02.014. Review.

PMID:
18343261
6.

Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis.

Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Nardone OM, De Vitis I, Papa A, Rapaccini GL, Guidi L.

Inflamm Bowel Dis. 2014 Aug;20(8):1368-74. doi: 10.1097/MIB.0000000000000115.

PMID:
24983979
7.

Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response.

Gonzalez-Lama Y, Fernandez-Blanco I, Lopez-SanRoman A, Taxonera C, Casis B, Tabernero S, Bermejo F, Martinez-Silva F, Mendoza JL, Martinez-Montiel P, Carneros JA, Sanchez F, Maté J, Gisbert JP; Group for the Study of Inflammatory Bowel Diseases from Madrid.

Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1609-14.

PMID:
19102352
8.

Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.

Jürgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, Wetzke M, Beigel F, Pfennig S, Stallhofer J, Schnitzler F, Tillack C, Lohse P, Göke B, Glas J, Ochsenkühn T, Brand S.

Am J Gastroenterol. 2010 Aug;105(8):1811-9. doi: 10.1038/ajg.2010.95. Epub 2010 Mar 2.

PMID:
20197757
9.

Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus.

Tsukamoto H, Tanida S, Mizoshita T, Ozeki K, Ebi M, Shimura T, Mori Y, Kataoka H, Kamiya T, Joh T.

Eur J Gastroenterol Hepatol. 2013 Jun;25(6):714-8. doi: 10.1097/MEG.0b013e32835eb999.

PMID:
23411870
10.
11.

Infliximab in patients with severe steroid-refractory ulcerative colitis: Indian experience.

Sood A, Midha V, Sharma S, Sood N, Bansal M, Thara A, Khanna P.

Indian J Gastroenterol. 2014 Jan;33(1):31-4. doi: 10.1007/s12664-013-0372-8. Epub 2013 Sep 3.

PMID:
23999683
12.

Clinical efficacy of infliximab in moderate to severe ulcerative colitis in a latin american referral population.

Juliao F, Marquez J, Aristizabal N, Yepes C, Zuleta J, Gisbert JP.

Digestion. 2013;88(4):222-8. doi: 10.1159/000355529. Epub 2013 Nov 22.

PMID:
24281150
13.

Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.

Subramaniam K, Richardson A, Dodd J, Platten J, Shadbolt B, Pavli P.

Intern Med J. 2014 May;44(5):464-70. doi: 10.1111/imj.12397.

PMID:
24612209
14.

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P; PURSUIT-SC Study Group.

Gastroenterology. 2014 Jan;146(1):85-95; quiz e14-5. doi: 10.1053/j.gastro.2013.05.048. Epub 2013 Jun 2.

PMID:
23735746
15.

Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.

Yamamoto S, Nakase H, Matsuura M, Honzawa Y, Masuda S, Inui K, Chiba T.

J Gastroenterol Hepatol. 2010 May;25(5):886-91. doi: 10.1111/j.1440-1746.2009.06206.x.

PMID:
20546441
16.

Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients.

Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M.

Dig Liver Dis. 2002 Sep;34(9):626-30.

PMID:
12405248
17.

Infliximab as a novel therapy for pediatric ulcerative colitis.

Mamula P, Markowitz JE, Brown KA, Hurd LB, Piccoli DA, Baldassano RN.

J Pediatr Gastroenterol Nutr. 2002 Mar;34(3):307-11.

PMID:
11964959
18.

A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis.

Huang X, Lv B, Jin HF, Zhang S.

Eur J Clin Pharmacol. 2011 Aug;67(8):759-66. doi: 10.1007/s00228-011-1079-3. Epub 2011 Jun 21. Review.

PMID:
21691804
19.

Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.

Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, Stein RB, Adler DR, Lichtenstein GR.

Am J Gastroenterol. 2002 Oct;97(10):2577-84.

PMID:
12385442
20.

Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.

Lawson MM, Thomas AG, Akobeng AK.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005112. Review.

PMID:
16856078
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk